Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 12/20 | 0.45 |
| ▸ | JAK3 | P52333 | 11/20 | 0.45 |
| ▸ | JAK2 | O60674 | 10/20 | 0.45 |
| ▸ | TYK2 | P29597 | 4/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918492 | 1.00 | JAK1 (0.45) | JAK1JAK3JAK2TYK2LRRK2 | |
| SCHEMBL12832959 | 0.81 | JAK3 (0.43) | JAK1JAK3JAK2TYK2LRRK2 | |
| SCHEMBL12832953 | 0.81 | JAK3 (0.43) | JAK1JAK3JAK2TYK2LRRK2 | |
| SCHEMBL9918497 | 0.79 | JAK2 (0.34) | JAK1JAK3JAK2 | |
| SCHEMBL9918494 | 0.74 | JAK2 (0.50) | JAK1JAK3JAK2TYK2LRRK2 | |
| SCHEMBL9918495 | 0.73 | JAK2 (0.44) | JAK1JAK3JAK2TYK2LRRK2 | |
| SCHEMBL9918480 | 0.72 | JAK3 (0.55) | JAK1JAK3JAK2TYK2LRRK2 | |
| SCHEMBL12832936 | 0.69 | JAK2 (0.36) | JAK1JAK3JAK2TYK2 | |
| SCHEMBL12832928 | 0.69 | LRRK2 (0.45) | JAK1JAK3JAK2TYK2LRRK2 | |
| SCHEMBL12888264 | 0.68 | JAK2 (0.80) | JAK1JAK3JAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | JAK1 2/4885JAK3 3/4885JAK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.